

DAFTAR PUSTAKA

1. Indonesia Pe. Pedoman Pengelolaan Dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa Di Indonesia 2021. Jakarta Perkumpulan Endokrinol Indones. 2021;
2. Magliano D, Boyko EJ. IDF diabetes atlas. 10th edition. Brussels: International Diabetes Federation; 2021.
3. Wahidin M, Achadi A, Besral B, Kosen S, Nadjib M, Nurwahyuni A, dkk. Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs. Sci Rep. 5 Maret 2024;14(1):5424.
4. Roy, S, Schweiker-Kahn, O, Jafry, B, Risk factors and comorbidities associated with diabetic kidney disease. Journal of primary journals.sagepub.com; 2021;. Available from: <https://doi.org/10.1177/21501327211048556>
5. Chan W. Chronic Kidney Disease and Nutrition Support. Vol 36, Nutrition in Clinical Practice. 2021. Hal 312 – 30.
6. Salem, D, Ekenga, V Vincent, Ekenga, C. ... Patterns of SGLT2 Inhibitors and GLP-1 RAs in Patients with Type 2 Diabetes and Comorbid Conditions of Cardiovascular Disease, Chronic Kidney Disease J Obes Chronic Dis. jobesitydiseases.com; 2022;. Available from: <https://jobesitydiseases.com/jocd/articles/v6n1/jocd-050-dunnya-salem.pdf>
7. Wang Y, Xu W, Mak IL, Chin WY, Yu EYT, Lam CLK, dkk. Trends of clinical parameters and incidences of diabetes mellitus complications among patients with type 2 diabetes mellitus in Hong Kong, 2010–2019: a retrospective cohort study. eClinicalMedicine. Juni 2023;60:101999.
8. Luigi, Gnudi., Janaka, Karalliedde. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrology Dialysis Transplantation, (2016).;31(7):1036-1043. doi: 10.1093/NDT/GFV093
9. Skrabic, R, Kumric, M, Vrdoljak, J, Rusic, D, Skrabic, I, SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice.

Biomedicines. mdpi.com; 2022;. Available from:
<https://www.mdpi.com/2227-9059/10/10/2458>

10. Henry, A., Spiller., Tama, S, Sawyer. Toxicology of oral antidiabetic medications. American Journal of Health-system Pharmacy, (2006).;63(10):929-938. doi: 10.2146/AJHP050500
11. Iijima Y, Nakayama M, Miwa T, Yakou F, Tomiyama H, Shikuma J, dkk. Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. Intern Med. 1 Maret 2023;62(5):681–8.
12. Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, dkk. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. Juni 2019;7(6):429–41.
13. Nelaj E, Feracaku J, Xhixhabesi K, Kecaj I, Tase M. Effect Of Dapagliflozin In Cardio And Renal Protection In Diabetic Patients. Journal of Hypertension. Mei 2024;42(Suppl 1):e143.
14. Organization Wh. Hearts D: Diagnosis And Management Of Type 2 Diabetes. World Health Organization; 2020.
15. Setiani La, Nurdin Nm, Rakasiwi Ia. Pengaruh Pemberian Pill Card Terhadap Kepatuhan Minum Obat Dan Tekanan Darah Responden Hipertensi Di Rs Pmi Kota Bogor. Fitofarmaka J Ilm Farm. 2021;11(1):51–66.
16. Sugihantono A. Percepatan Pencegahan Dan Pengendalian Penyakit Menuju Cakupan Kesehatan Semesta. Rakerkesda Provinsi Jawa Tengah. [https://dinkesjatengprov. Go. Id](https://dinkesjatengprov.go.id); 2019.
17. Association Ad. Standards Of Medical Care In Diabetes—2021 Abridged For Primary Care Providers. Clin Diabetes A Publ Am Diabetes Assoc. 2021;39(1):14.
18. Decroli E. Diabetes Melitus Tipe 2. Padang Pus Pnb Bagian Ilmu Penyakit Dalam Fak Kedokt Univ Andalas. 2019;1–52.
19. Dharma S. Buku Ajar Praktis Patofisiologi Farmakologi & Farmakoterapi. Yogyakarta Gre Publ. 2016;

20. Federation Id. IDF Diabetes Atlas Ninth. Dunia Idf. 2019;168.
21. Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg Ew, Et Al. Mortality Attributable To Diabetes In 20–79 Years Old Adults, 2019 Estimates: Results From The International Diabetes Federation Diabetes Atlas. *Diabetes Res Clin Pract.* 2020;162:108086.
22. Kemenkes RI. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Badan Penelitian Dan Pengembangan. Jakarta. 2018.
23. Padang Dk. Laporan Tahunan Tahun 2021 Edisi Tahun 2022 [Internet]. Dinkes Kota Padang. Padang; 2022. Available From: <https://Dinkes.Padang.Go.Id/Laporan-Tahunan-Tahun-2021-Edisi-Tahun-2022>. s 48
24. Federation Id. IDF Diabetes Atlas 8th Edition. *Int Diabetes Fed.* 2017;905–11.
25. Snyder C, Berman At, Frandsen G, Snyder S. Kozier & Erb's Fundamentals Of Nursing, Ebook, Global Eition. Pearson Higher Ed; 2016.
26. Bilous R, Donnelly R, Idris I. *Handbook Of Diabetes.* John Wiley & Sons; 2021.
27. Li L, Li S, Liu J, Deng K, Busse Jw, Vandvik Po, Et Al. Glucagon- Like Peptide-1 Receptor Agonists And Heart Failure In Type 2 Diabetes: Systematic Review And Meta-Analysis Of Randomized And Observational Studies. *Bmc Cardiovasc Disord.* 2016;16(1):1– 14.
28. Roopa, Naik., Raja, Ramachandran., Bushra, Firdous, Shaik., Atul, Bali. Diabetic Kidney Disease. (2023).35-53. doi: 10.9734/bpi/mono/978-81-19491-84-1/ch3
29. Keizo, Kanasaki., Kohjiro, Ueki., Masaomi, Nangaku. Diabetic kidney disease: the kidney disease relevant to individuals with diabetes. *Clinical and Experimental Nephrology*, (2024). doi: 10.1007/s10157-024-02537-z
30. Mai, Sugahara., Wai, Lun, Will, Pak., Tetsuhiro, Tanaka., Sydney, C.W., Tang., Masaomi, Nangaku. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.. *Nephrology*, (2021).;26(6):491-500. doi: 10.1111/NEP.13860

31. Chen, Fang., Liyan, Sun., Yan, Liu., Li, Xiao., Lin-Yin, Sun. A review of nonclassical clinical types and pathological changes in diabetic kidney disease. (2023). ;54:1074-1079. doi: 10.12182/20231160102
32. Moarij, Qaz., Hanny, Sawaf., Jeeda, Ismail., Humaira, Qazi., Tushar, J., Vachharajani. Pathophysiology of Diabetic Kidney Disease. European medical journal, (2022).102-113. doi: 10.33590/emjnephrol/22-00060
33. Ron, T., Varghese., Ishwarlal, Jialal., Chaddie, Doerr. Diabetic Nephropathy (Nursing). (2021).
34. Duan X, Wang L, Wei W, Wang Z, Zhang X, Liu J, dkk. Chronic kidney disease and functional impairment in a longitudinal study of older adults in China. BMJ Open. November 2023;13(11):e074819.
35. Corsonello A, Soraci L, Ärnlov J, Carlsson AC, Roller-Wirnsberger R, Wirnsberger G, dkk. The relevance of geriatric assessments on the association between chronic kidney disease stages and mortality among older people: a secondary analysis of a multicentre cohort study. Age and Ageing. 1 Juli 2022;51(7):afac168.
36. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, dkk. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Diseases. Mei 2014;63(5):713–35.
37. DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod VL, editor. Pharmacotherapy: a pathophysiologic approach. 11th edition. New York: McGraw Hill Medical; 2020.
38. PNPk 2023 - Tata Laksana Penyakit Ginjal Kronik. (2023, October 11). Wwww.kemkes.go.id. <https://www.kemkes.go.id/id/pnpk-2023---tata-laksana-penyakit-ginjal-kronik>
39. Whittlesea C, Hodson K. Clinical Pharmacy and Therapeutics. Sixth. Elsevier Limited; 2019.
40. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and Renal Fibrosis. Hypertension. September 2001;38(3):635–8.

41. Gu YY, Dou JY, Huang XR, Liu XS, Lan HY. Transforming Growth Factor- β and Long Non-coding RNA in Renal Inflammation and Fibrosis. *Front Physiol.* 13 Mei 2021;12:684236.
42. Tsushima Y, Lansang MC, Makin V. The role of SGLT-2 inhibitors in managing type 2 diabetes. *CCJM.* Januari 2021;88(1):47–58.
43. Vart P, Butt JH, Jongs N, Schechter M, Chertow GM, Wheeler DC, dkk. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. Fielding R, editor. *The Journals of Gerontology: Series A.* 1 Februari 2024;79(2):glad181.
44. Laursen JC, Søndergaard-Heinrich N, De Melo JML, Haddock B, Rasmussen IKB, Safavimanesh F, dkk. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. *eClinicalMedicine.* Juli 2021;37:100895.
45. Liu ZZ, Bullen A, Li Y, Singh P. Renal Oxygenation in the Pathophysiology of Chronic Kidney Disease. *Front Physiol.* 28 Juni 2017;8:385.
46. Clemmer JS, Yen TE, Obi Y. Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease. *Physiological Reports.* November 2023;11(21):e15836.
47. Davis KN, Hines AE, Schaefer MC, Naseman KW. Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy. *Clinical Diabetes.* 1 Juli 2022;40(3):305–11.
48. Vivian EM. Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. *American Journal of Health-System Pharmacy.* 1 Maret 2015;72(5):361–72.
49. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. *Cardiovasc Diabetol.* Desember 2015;14(1):142.
50. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, dkk. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes Obesity Metabolism.* Mei 2014;16(5):433–42.

51. Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. *CJASN*. Agustus 2022;17(8):1220–33.
52. Fogo AB, Lusco MA, Najafian B, Alpers CE. *AJKD Atlas of Renal Pathology: Toxic Acute Tubular Injury*. American Journal of Kidney Diseases. Juni 2016;67(6):e31–2.
53. Fogo AB, Lusco MA, Najafian B, Alpers CE. *AJKD Atlas of Renal Pathology: Ischemic Acute Tubular Injury*. American Journal of Kidney Diseases. Mei 2016;67(5):e25.
54. Schurder J, Buob D, Perrin P, Thervet E, Karras A, Hertig A. Acute interstitial nephritis: aetiology and management. *Nephrology Dialysis Transplantation*. 27 September 2021;36(10):1799–802.
55. Perazella MA, Herlitz LC. The Crystalline Nephropathies. *Kidney International Reports*. Desember 2021;6(12):2942–57.
56. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. *Endocrine Reviews*. 1 Juni 2017;38(3):173–88.
57. Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, dkk. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*. Maret 2020;63(3):453–61.
58. Jeong SJ, Lee SE, Shin DH, Park IB, Lee HS, Kim KA. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. *BMC Nephrol*. Desember 2021;22(1):177.
59. Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Mulvey MA, Stapleton AE, Klumpp DJ, editor. *Microbiol Spectr*. 23 Desember 2016;4(6):4.6.37.
60. Kim KS, Kim SK, Sung KM, Cho YW, Park SW. Management of Type 2 Diabetes Mellitus in Older Adults. *Diabetes Metab J*. 2012;36(5):336.
61. Chonko K, Russo-Alvarez G, Isaacs D, Wang L, Soric A. Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate. *Innov Pharm*. 26 Juni 2023;14(2):9.

62. Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly [Internet]. 13 September 2012 [dikutip 3 Februari 2025]; Tersedia pada: <https://smw.ch/index.php/smw/article/view/1582>
63. Vart P, Jongs N, Wheeler DC, Heerspink HJL, Langkilde AM, Chertow GM. Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 27 April 2023;6(4):e2310877.
64. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, dkk. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes— post hoc analyses from the DECLARE-TIMI 58 trial [Internet]. American Diabetes Association. 2022 [dikutip 5 Januari 2025]. Tersedia pada: https://diabetesjournals.figshare.com/articles/figure/Dapagliflozin_and_prevention_of_kidney_disease_among_patients_with_type_2_diabetes_post_hoc_analyses_from_the_DECLARE-TIMI_58_trial/20365530
65. Nadkarni GN, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P, dkk. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care. 1 November 2017;40(11):1479–85.
66. Tanaka H. #5770 Proposing A New Renal Outcome When Reaching Estimated Gfr Of 30—Simulation Study Using Real-World Stratified Data. Nephrology Dialysis Transplantation. 14 Juni 2023;38(Supplement_1):gfa063c_5770.
67. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. Juni 2016;29(3):391–400.
68. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, dkk. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 8 Oktober 2020;383(15):1436–46.
69. Ryo, Shibata., Kensei, Taguchi., Yusuke, Kaida., Kei, Fukami. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic

- kidney disease patients without diabetes mellitus. *Clinical and Experimental Nephrology*, (2022).;27(1):44-53. doi: 10.1007/s10157-022-02277-y.
70. Moriconi D, Sacchetta L, Chiriaco M, Nesti L, Forotti G, Natali A, dkk. Glomerular Hyperfiltration Predicts Kidney Function Decline and Mortality in Type 1 and Type 2 Diabetes: A 21-Year Longitudinal Study. *Diabetes Care*. 1 April 2023;46(4):845–53.
71. Zhao JV, Schooling CM. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank. *BMC Med*. Desember 2020;18(1):122.
72. Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. *Curr Diab Rep*. Januari 2022;22(1):39–52.
73. Neugarten J, Golestaneh L. Influence of Sex on the Progression of Chronic Kidney Disease. *Mayo Clinic Proceedings*. Juli 2019;94(7):1339–56.
74. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nat Rev Nephrol*. Maret 2018;14(3):151–64.
75. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, dkk. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study. *Diabetes Care*. 1 Februari 2020;43(2):468–75.
76. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the Vascular Endothelium. *Annals of the New York Academy of Sciences*. Juni 2002;966(1):143–57.
77. Yu M, Vart P, Heerspink HL, Jong N, Correa-Rotter R, McMurray J, dkk. #3669 Effect Of Dapagliflozin In Patients With Ckd Across The Spectrum Of Age And By Sex. *Nephrology Dialysis Transplantation*. 14 Juni 2023;38(Supplement_1):gfad063c_3669.
78. McMurray JJV, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, dkk. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. *Circulation*. 2 Februari 2021;143(5):438–48.

79. World Health Organization. Classification of diabetes mellitus [Internet]. Geneva: World Health Organization; 2019 [dikutip 16 Februari 2025]. 36 hlm. Tersedia pada: <https://iris.who.int/handle/10665/325182>
80. Nanayakkara N, Curtis AJ, Heritier S, Gadowski AM, Pavkov ME, Kenealy T, dkk. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. *Diabetologia*. Februari 2021;64(2):275–87.
81. Common questions about dapagliflozin [Internet]. nhs.uk. 2022. Available from: <https://www.nhs.uk/medicines/dapagliflozin/common-questions-about-dapagliflozin/>
82. Kim YG, Moon JY, Oh B, Chin HJ, Kim DK, Park JH, dkk. Pressure-Natriuresis Response Is Diminished in Old Age. *Front Cardiovasc Med*. 16 Februari 2022;9:840840.
83. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin–Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. *High Blood Press Cardiovasc Prev*. Juni 2018;25(2):137–45.
84. Naughton CA. Drug-Induced Nephrotoxicity. *American Family Physician* [Internet]. 2008 Sep 15;78(6):743–50. Available from: <https://www.aafp.org/pubs/afp/issues/2008/0915/p743.html>
85. Rasha, O., Abdelmoniem., M., S., Shaalan., Mohamed, Shawky., Walla, M., Ibrahim., Ayman, M., Elbadawy. Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients. *The Egyptian Journal of Hospital Medicine*, (2022).;88(1):2923-2929. doi: 10.21608/ejhm.2022.242996.
86. Search | European Medicines Agency (EMA) [Internet]. European Medicines Agency (EMA). 2011 [cited 2025 Jan 14]. Available from: https://www.ema.europa.eu/en/search?search_api_fulltext=forxiga&f%5B0%5D=ema_search_entity_is_document%3ADocument
87. Rasha, O., Abdelmoniem., M., S., Shaalan., Mohamed, Shawky., Walla, M., Ibrahim., Ayman, M., Elbadawy. Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients. *The*

- Egyptian Journal of Hospital Medicine, (2022).;88(1):2923-2929. doi: 10.21608/ejhm.2022.242996.
88. Oh TJ, Moon JY, Hur KY, Ko SH, Kim HJ, Kim T, dkk. Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. *Diabetes Metab J*. 2020;44(4):489.
89. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney International*. April 2014;85(4):962–71.
90. Maki, Murakoshi., Takashi, Kobayashi., Masao, Kihara., Seiji, Ueda., Yusuke, Suzuki., Tomohito, Gohda. The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease.. *Nephrology*, (2023). doi: 10.1111/nep.14207.
91. Van Bommel EJM, Muskiet MHA, Van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, dkk. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. *Kidney International*. Januari 2020;97(1):202–12.
92. Baskoy G, Qin Y, Cersosimo E, Solis-Herrera C, Adams JM, Defronzo RA, dkk. 887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients. *Diabetes*. 20 Juni 2023;72(Supplement_1):887-P.
93. Iversen E, Nielsen LJ, Curovic VR, Walls AB, Eickhoff MK, Frimodt-Møller M, dkk. Effect of Dapagliflozin on Measured vs. Panel-Estimated Glomerular Filtration Rate. *Clin Pharma and Therapeutics*. Februari 2025;117(2):515–22.